Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Risperidone

FDA-approved product (tablet, oral), marketed as Perseris Kit, Risperdal, Risperdal Consta and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Risperidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aggressive behavior
  • Autism
  • Bipolar disorder
  • Bipolar I disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Risperidone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Risperidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients

    NCT01086748 · start 2010-03

    Registered record
    Registry ID
    NCT01086748
    Conditions
    Schizophrenia
    Interventions
    Risperidone; Placebo; LY2140023
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03
    Completion
    2012-05
    Enrolment
    1,134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone; Placebo; LY2140023
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

    NCT01050582 · start 2009-10

    Registered record
    Registry ID
    NCT01050582
    Conditions
    Schizophrenia; Bipolar Disorder; Autistic Disorder; Conduct and Other Disruptive Behavior Disorders
    Interventions
    Risperidone; Other atypical antipsychotic drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-10
    Completion
    2011-07
    Enrolment
    244

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Bipolar Disorder; Autistic Disorder; Conduct and Other Disruptive Behavior Disorders
    InterventionRisperidone; Other atypical antipsychotic drugs
    PhasePhase 4
    Registry statusCompleted

  • Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

    NCT00827840 · start 2008-11

    Registered record
    Registry ID
    NCT00827840
    Conditions
    Schizophrenia
    Interventions
    Paliperidone ER; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-11
    Completion
    2011-02
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone ER; Risperidone
    PhasePhase 4
    Registry statusCompleted

  • Dementia Antipsychotics And Antidepressants Discontinuation Study

    NCT00594269 · start 2008-08

    Registered record
    Registry ID
    NCT00594269
    Conditions
    Dementia
    Interventions
    Risperidone; Escitalopram; Citalopram; Sertraline; Paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-08
    Completion
    2010-12
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia
    InterventionRisperidone; Escitalopram; Citalopram; Sertraline +1 more
    PhasePhase 4
    Registry statusCompleted

  • Juvenile Bipolar Disorder Outpatient Program

    NCT01000402 · start 2008-02

    Registered record
    Registry ID
    NCT01000402
    Conditions
    Bipolar Disorder; Attention Deficit Disorder With Hyperactivity
    Interventions
    Psychopharmacotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-02
    Completion
    2014-11
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Attention Deficit Disorder With Hyperactivity
    InterventionPsychopharmacotherapy
    PhasePhase 4
    Registry statusUnknown

  • Pharmacogenomics in Autism Treatment

    NCT00584701 · start 2008-01

    Registered record
    Registry ID
    NCT00584701
    Conditions
    Autism
    Interventions
    Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-05
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism
    InterventionRisperidone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study Evaluating Vabicaserin in Subjects With Schizophrenia

    NCT00563706 · start 2007-12

    Registered record
    Registry ID
    NCT00563706
    Conditions
    Schizophrenia
    Interventions
    vabicaserin; risperidone; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-06
    Enrolment
    199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionvabicaserin; risperidone; placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

    NCT00576732 · start 2007-12

    Registered record
    Registry ID
    NCT00576732
    Conditions
    Autistic Disorder; Autism
    Interventions
    Placebo; Risperidone high dose; Risperidone low dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-12
    Completion
    2010-03
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutistic Disorder; Autism
    InterventionPlacebo; Risperidone high dose; Risperidone low dose
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

    NCT00391222 · start 2006-11

    Registered record
    Registry ID
    NCT00391222
    Conditions
    Bipolar Disorder
    Interventions
    Olanzapine; Placebo; Risperidone Long Acting Injectable (LAI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-11
    Completion
    2009-04
    Enrolment
    585

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionOlanzapine; Placebo; Risperidone Long Acting Injectable (LAI)
    PhasePhase 3
    Registry statusCompleted

  • Metabolic Profile and Anthropometric Changes in Schizophrenia

    NCT00534183 · start 2006-06

    Registered record
    Registry ID
    NCT00534183
    Conditions
    Metabolic Syndrome; Diabetes; Obesity
    Interventions
    Olanzapine; Risperidone; Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-06
    Completion
    2006-12
    Enrolment
    2,006

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Syndrome; Diabetes; Obesity
    InterventionOlanzapine; Risperidone; Haloperidol
    PhaseNot applicable
    Registry statusCompleted

  • First Episode Schizophrenia and Cannabis-Related Disorder Study

    NCT00573287 · start 2006-06

    Registered record
    Registry ID
    NCT00573287
    Conditions
    Cannabis-Related Disorder; Substance-Related Disorders; Schizophrenia; Psychotic Disorders
    Interventions
    clozapine; risperidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-06
    Completion
    2011-12
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabis-Related Disorder; Substance-Related Disorders; Schizophrenia; Psychotic Disorders
    Interventionclozapine; risperidone
    PhaseNot applicable
    Registry statusCompleted

  • Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.

    NCT00828958 · start 2006-02

    Registered record
    Registry ID
    NCT00828958
    Conditions
    Schizophrenia
    Interventions
    Risperidone long-acting injectable
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-02
    Completion
    2006-09
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone long-acting injectable
    PhasePhase 3
    Registry statusCompleted

  • Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode

    NCT00216671 · start 2005-11

    Registered record
    Registry ID
    NCT00216671
    Conditions
    Schizophrenia
    Interventions
    early initiation of treatment with Risperdal Consta; routine initiation of treatment with Risperdal Consta
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-11
    Completion
    2009-12
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionearly initiation of treatment with Risperdal Consta; routine initiation of treatment with Risperdal Consta
    PhasePhase 4
    Registry statusCompleted

  • Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

    NCT00130923 · start 2005-09

    Registered record
    Registry ID
    NCT00130923
    Conditions
    Schizophrenia; Psychotic Disorders; Substance Abuse; Alcohol Abuse
    Interventions
    Risperidone Long Acting; oral risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-09
    Completion
    2010-07
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychotic Disorders; Substance Abuse; Alcohol Abuse
    InterventionRisperidone Long Acting; oral risperidone
    PhasePhase 4
    Registry statusCompleted

  • Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence

    NCT00385801 · start 2005-09

    Registered record
    Registry ID
    NCT00385801
    Conditions
    Cocaine Dependence
    Interventions
    Risperidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-09
    Completion
    2010-09
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Dependence
    InterventionRisperidone; Placebo
    PhasePhase 2
    Registry statusCompleted